Eastgate Biotech (ETBI) 10-Q/A 1 Mar 18 2016 Q2 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Feb. 27, 2018
Document and Entity Information:
Entity Registrant Name	EASTGATE BIOTECH CORP
Entity Central Index Key	1,099,574
Trading Symbol	etbi
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		934,305,508
Document Type	10-Q/A
Document Period End Date	Jun. 30, 2016
Amendment Flag	true
Amendment Description	We are filing this Amendment No. 1 on Form 10-Q/A to amend and restate in their entirety the following items of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 as originally filed with the Securities and Exchange Commission on February 27, 2017 (the “Original Form 10-Q”): (i) Item 1 of Part I “Financial Information,” (ii) Item 2 of Part I, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” (iii) Item 4 of Part I, “Controls and Procedures,” and (iv) Item 6 of Part II, “Exhibits”, and we have also updated the signature page, the certifications of our Chief Executive Officer and President, treasurer and coporate secretaryin Exhibits 31.1, 31.2, 32.1 and 32.2, and our financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibits 101. No other sections were affected, but for the convenience of the reader, this report on Form 10-Q/A restates in its entirety, as amended, our Original Form 10-Q. This report on Form 10-Q/A is presented as of the filing date of the Original Form 10-Q and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatement described below. On or about May 3, 2017, the Board of Directors, upon the recommendation of the Company’s management and after discussions with our then current independent registered public accounting firm, Sadler, Gibb & Associates, LLC (“Sadler”), concluded that the quarterly financial statements for the periods ended March 31, 2016, June 30, 2016 and September 30, 2016 (collectively, the “Non-Reliance Periods”) as previously issued should no longer be relied upon (the “Non-Reliance Determination”). The Company made the Non-Reliance Determination because the quarterly financial statements had been filed without Sadler;s review. Our quarterly financial statements have been restated to correct errors in the Original 10-Q. We have made necessary conforming changes in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” resulting from the correction of such errors in the Original 10-Q
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current
Cash	$ 72,543	$ 19,241
Deposits		14,595
Sales tax recoverable		79,681
Total current assets	72,543	113,517
Other assets
Property & Equipment, net		184,402
Total other assets		184,402
Total assets	72,543	297,919
Current liabilities
Accounts payable and accrued liabilities	285,346	361,094
Deferred revenue	94,166	23,847
Accrued liabilities related party	1,484,349	732,125
Deferred rent	1,430	2,064
Capital lease obligation	8,453	8,130
Accrued interest - related parties	359,121	292,769
Notes payable - related parties	1,468,262	1,308,585
Total current liabilities	3,701,127	2,728,614
Long term liabilities
Capital lease obligation long term	48,091	50,386
Total Liabilities	3,749,218	2,779,000
Commitments and Contingencies
Stockholders' deficit
Authorized: Preferred stock:50,000,000 shares authorized at $0.00001 par value no shares issued at June 30, 2016 and December 31, 2015
Common stock: 450,000,000 shares authorized at $0.00001 par value 306,272,175 and 282,872,175 shares issued and outstanding at June 30, 2016 and December 31, 2015 respectively	3,063	2,829
Additional paid-in capital	9,891,010	9,137,764
Accumulated other comprehensive income	17,706	31,846
Deficit accumulated	(13,588,454)	(11,653,520)
Total stockholders' deficit	(3,676,675)	(2,481,081)
Total liabilities and stockholders' deficit	$ 72,543	$ 297,919

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Stockholders' deficit
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	450,000,000	450,000,000
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, issued	306,272,175	282,872,175
Common stock, outstanding	306,272,175	282,872,175

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Condensed Consolidated Statements Of Operations And Comprehensive Loss
REVENUES		$ 58,543		$ 58,543
Cost of goods sold		8,430		8,430
Gross (loss) profit		50,113		50,113
OPERATING EXPENSES
Professional fees	1,669	46,783	4,305	97,203
Research & development	126,873	297,858	265,514	693,978
General and administrative	231,815	455,427	1,264,035	1,509,702
Marketing and selling	69,659	50,551	139,940	319,736
Total Operating Expenses	430,016	850,619	1,673,794	2,620,619
LOSS FROM OPERATIONS	(430,016)	(800,506)	(1,673,794)	(2,570,506)
Other items
Interest expense	(41,402)	(26,703)	(76,738)	(49,353)
Losses from Impairment of Assets			(184,402)
Total other items	(41,402)	(26,703)	(261,140)	(49,353)
LOSS BEFORE INCOME TAXES	(471,418)	(827,209)	(1,934,934)	(2,619,859)
PROVISION FOR INCOME TAXES
NET LOSS	$ (471,418)	$ (827,209)	$ (1,934,934)	$ (2,619,859)
BASIC AND DILUTED LOSS PER SHARE	$ (0.002)	$ (0.01)	$ (0.01)	$ (0.02)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED	306,272,175	154,771,152	302,286,461	132,514,850
COMPREHENSIVE LOSS
Net Loss	$ (471,418)	$ (827,209)	$ (1,934,934)	$ (2,619,859)
Other Comprehensive Loss - foreign currency translation	1,484	(5,224)	(14,140)	(5,312)
Comprehensive Loss	$ (469,934)	$ (832,433)	$ (1,949,074)	$ (2,625,171)

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-In Capital	Subscription Payable	Accumulated other comprehensive income	Deficit Accumulated During the Development Stage	Total
Begnning Balance, Shares at Dec. 31, 2014	89,635,234
Begnning Balance, Amount at Dec. 31, 2014	$ 896	$ 5,957,771		$ 15,268	$ (7,372,210)	$ (1,398,275)
Shares issued in conversion of accrued compensation, Shares	117,898,608
Shares issued in conversion of accrued compensation, Amount	$ 1,179	1,236,151
Shares issued for services, Shares	24,253,333
Shares issued for services, Amount	$ 243	560,351
Stock options and warrants issued, Amount		488,351
Shares issued for Acquisition of Assets/Lease, Shares	1,500,000
Shares issued for Acquisition of Assets/Lease, Amount	$ 15	20,985
Private placement shares and warrants issued for cash, Shares	335,000
Private placement shares and warrants issued for cash, Amount	$ 3	24,997
Shares issued for bonus, Shares	49,250,000
Shares issued for bonus, Amount	$ 493	849,158
Foreign Currency Transaltion adjustments				16,578
Net loss for the Year ended					(4,281,310)
Ending Balance, Shares at Dec. 31, 2015	282,872,175
Ending Balance, Amount at Dec. 31, 2015	$ 2,829	9,137,764	0	31,846	(11,653,520)	(2,481,081)
Shares issued in conversion of accrued compensation, Shares
Shares issued in conversion of accrued compensation, Amount
Shares issued for services, Shares	23,400,000
Shares issued for services, Amount	$ 234	753,246				753,480
Stock options and warrants issued, Amount
Shares issued for Acquisition of Assets/Lease, Shares
Shares issued for Acquisition of Assets/Lease, Amount
Foreign Currency Transaltion adjustments				(14,140)		(14,140)
Net loss for the Year ended					(1,934,934)	(1,934,934)
Ending Balance, Shares at Jun. 30, 2016	306,272,175
Ending Balance, Amount at Jun. 30, 2016	$ 3,063	$ 9,891,010		$ 17,706	$ (13,588,454)	$ (3,676,675)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$ (1,934,934)	$ (2,619,859)
Adjustments to reconcile net loss to net cash used by operating activities:
Expenses paid on the Company's behalf by a related party	(1,827)
Common stock issued for services	753,480	1,077,743
Depreciation		18,564
Losses from Impairment of Assets	184,402
Stock options issued		291,427
Changes in operating assets and liabilities:
Accrued interest	66,352	49,353
Prepaid asset	14,595	(6,597)
Accounts payable	2,028	49,242
Accrued liabilities related party	745,639	725,452
Reserve for Recoverable Tax	(9,606)	(24,436)
Deferred rent	(760)	(820)
Deferred revenue	66,950	9,831
Cash flows used in operating activities	(113,681)	(430,100)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of capital lease obligation	(1,973)
Proceeds from notes payable related party	161,505	159,750
Payments on notes payable related party		(5,536)
Cash overdraft		6,611
Cash flows provided by financing activities	159,532	160,825
NET INCREASE (DECREASE) IN CASH	45,851	(269,275)
Effect of foreign currency translation adjustments	7,451	(17,206)
Cash, beginning of the period	19,241	286,481
Cash, end of the period	72,543
Supplemental disclosures of cash flow information:
Cash paid for income taxes
Cash paid for interest	6,027
Non Cash Financing activities:
Common stock issued to convert liabilities		$ 761,849

CONDENSED FINANCIAL STATEMENTS

CONDENSED FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
NOTE 1 - CONDENSED FINANCIAL STATEMENTS	The accompanying financial statements have been prepared by the Eastgate Biotech Corp without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2016, and for all periods presented herein have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2015 audited financial statements. The results of operations for the periods ended June 30, 2016 and 2015 are not necessarily indicative of the operating results for the full years.

GOING CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
NOTE 2 - GOING CONCERN	The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has accumulated deficit of $13,588,454 as of June 30, 2016. The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time, raising substantial doubt about its ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES	Principles of Consolidation The consolidated financial statements include the accounts of Eastgate Biotech Corp. and its wholly-owned subsidiary Eastgate Pharmaceuticals Inc. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of six months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Research and Development Costs The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration. Foreign Currency Translation Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary’s financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders’ equity. Recent Accounting Pronouncements In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information. The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
NOTE 4 - RELATED-PARTY TRANSACTIONS	Notes payable – related parties The Company has recorded loans from shareholders, amounts due to shareholders for expenses paid on its behalf by shareholders as Notes payable - related parties on the balance sheet. The amounts comprising Notes payable – related parties bear interest ranging from 5 percent per annum to 10 percent per annum, are unsecured and are due and payable upon demand. During the six months ended June 30, 2016 the CEO and companies owned by the CEO as well as a company owned by a related party shareholder have advanced cash to the Company of $161,505, and have had expenses paid by the Company of $1,827 on their behalf. At June 30, 2016 the Company has not repaid any of related party loans. During the year ended December 31, 2015 the CEO and the current President advanced the company cash of $310,825 and were repaid $5,536 of advances made. In addition during this period they paid $2,337 of expenses on behalf of the company and were reimbursed for $5,432 in expenses they previously paid. This accounts for the increase in notes payable related party for the year ended December 31, 2015 of $302,194. As of June 30, 2016 and December 31, 2015, the Company owed $359,121 and $292,769 of accrued interest to related parties, respectively, resulting from interest expense of $66,322 and $109,954, respectively.

SALES TAX RECOVERABLE

SALES TAX RECOVERABLE	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
NOTE 5 –SALES TAX RECOVERABLE	Sales tax receivable The Company recovers sales tax paid, for which returns are filed on annual basis but company was able to file the return only in 2017. This is reserved as of June 30, 2016, The Balance of $95,149 was claimed as recoverable compared to the December 31, 2015 balance of $79,681. Sales tax recoverable is a result of sales tax paid on eligible expenses.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
NOTE 6 – STOCKHOLDERS DEFICIT	On February 1 st st The following table summarizes the stock options that are issued, outstanding and exercisable Stock Options Issued & Outstanding Exercise Expiration June 30 December 31 Price Date 2016 2015 $ 0.286 February 12, 2020 10,375,000 10,375,000 As of June 30, 2016, the Company had 41,164,901 warrants to purchase common stock. All outstanding warrants have a weighted average price of $0.07 per share and have a weighted average remaining life of 3.06 years. The following table summarizes warrants that are issued, outstanding and exercisable Warrants Issued & Outstanding Exercise Expiration June 30 December 31 Price Date 2016 2015 $ 0.25 March 14, 2019 3,495,000 3,495,000 $ 0.25 March 21, 2019 3,480,000 3,480,000 $ 0.25 June 6, 2019 2,022,300 2,022,300 $ 0.05 October 16, 2019 150,000 150,000 0.04 December 31, 2019 8,125,000 8,125,000 $ 0.04 January 5, 2020 8,146,225 8,146,225 0.04 August 19, 2020 125,000 125,000 0.00001 October 6, 2020 15,621,376 16,171,627 41,164,901 41,715,152

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
NOTE 7 - SUBSEQUENT EVENTS	In accordance with ASC 855 Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report except as described below: On January 1 st On February 1 st

SIGNIFICANT ACCOUNTING POLICI14

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2016
Significant Accounting Policies Policies
Principles of Consolidation	The consolidated financial statements include the accounts of Eastgate Biotech Corp. and its wholly-owned subsidiary Eastgate Pharmaceuticals Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of six months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
Research and Development Costs	The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.
Foreign Currency Translation	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary’s financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders’ equity.
Recent Accounting Pronouncements	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information. The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	6 Months Ended
	Jun. 30, 2016
Summarizes warrants that are issued, outstanding and exercisable	Warrants Issued & Outstanding Exercise Expiration June 30 December 31 Price Date 2016 2015 $ 0.25 March 14, 2019 3,495,000 3,495,000 $ 0.25 March 21, 2019 3,480,000 3,480,000 $ 0.25 June 6, 2019 2,022,300 2,022,300 $ 0.05 October 16, 2019 150,000 150,000 0.04 December 31, 2019 8,125,000 8,125,000 $ 0.04 January 5, 2020 8,146,225 8,146,225 0.04 August 19, 2020 125,000 125,000 0.00001 October 6, 2020 15,621,376 16,171,627 41,164,901 41,715,152
Stock Option [Member]
Summarizes warrants that are issued, outstanding and exercisable	Stock Options Issued & Outstanding Exercise Expiration June 30 December 31 Price Date 2016 2015 $ 0.286 February 12, 2020 10,375,000 10,375,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Going Concern Details Narrative
Accumulated deficit	$ (13,588,454)	$ (11,653,520)

RELATED-PARTY TRANSACTIONS (Det

RELATED-PARTY TRANSACTIONS (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Proceeds from notes payable related party	$ 161,505	$ 159,750
Expenses paid on the Company's behalf by a related party	1,827
Repayment of related party loan		$ 5,536
Accrued interest to related parties	$ 359,121		$ 292,769
Minimum [Member]
Related Party Transaction [Line Items]
Annual interest rate	5.00%
Maximum [Member]
Related Party Transaction [Line Items]
Annual interest rate	10.00%
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accrued interest to related parties	$ 359,121		292,769
Chief Executive Officer [Member] | Notes Payable [Member]
Related Party Transaction [Line Items]
Proceeds from notes payable related party	161,505		310,825
Expenses paid on the Company's behalf by a related party	1,827		2,337
Repayment of related party loan			5,536
Reimbursment of expense			5,432
Interest expense	$ 66,322		109,954
Increase in notes payable			$ 302,194

SALES TAX RECOVERABLE (Details

SALES TAX RECOVERABLE (Details Narrative) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Sales Tax Recoverable Details Narrative
Sales tax recoverable	$ 95,149	$ 79,681

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Warrants Issued & Outstanding	41,164,901	41,715,152
Stock Option [Member] | Option Expiration Date February 12, 2020 [Member]
Exercise Price	$ 0.286	$ 0.286
Warrants Issued & Outstanding	10,375,000	10,375,000

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details 1) - $ / shares	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Warrants Issued & Outstanding		41,164,901	41,715,152
Warrants Expiration Date 14 March 2019 [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 0.25	$ 0.25
Warrants Issued & Outstanding		3,495,000	3,495,000
Warrants Expiration Date 21 March 2019 [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 0.25	$ 0.25
Warrants Issued & Outstanding		3,480,000	3,480,000
Warrants Expiration Date 6 June 2019 [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 0.25	$ 0.25
Warrants Issued & Outstanding		2,022,300	2,022,300
Warrants Expiration Date 16 October 2019 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.05	$ 0.05
Warrants Issued & Outstanding	150,000	150,000
Warrants Expiration Date 31 December 2019 [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 0.04	$ 0.04
Warrants Issued & Outstanding		8,125,000	8,125,000
Warrants Expiration Date 5 january 2020 [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 0.04	$ 0.04
Warrants Issued & Outstanding		8,146,225	8,146,225
Warrants Expiration Date 19 August 2020 [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 0.04	$ 0.04
Warrants Issued & Outstanding		125,000	125,000
Warrants Expiration Date 6 October 2020 [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 0.00001	$ 0.00001
Warrants Issued & Outstanding		15,621,376	16,171,627

STOCKHOLDERS' DEFICIT (Detail21

STOCKHOLDERS' DEFICIT (Details Narrative) - $ / shares	1 Months Ended	6 Months Ended
	Feb. 01, 2016	Jun. 30, 2016	Dec. 31, 2015
Stockholders Equity Note [Line Items]
Number of warrants to purchase common stock		41,164,901	41,715,152
Warrants [Member]
Stockholders Equity Note [Line Items]
Number of warrants to purchase common stock		41,164,901
Weighted average price per share		$ 0.07
Weighted average life		3 years 22 days
Consultants [Member]
Stockholders Equity Note [Line Items]
Shares issued for services rendered (in shares)	23,400,000
Price per share	$ 0.0322

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	Feb. 01, 2017Integershares	Jan. 01, 2017Integershares	Jun. 30, 2016shares	Dec. 31, 2015shares
Common stock, shares issued for compensation			306,272,175	282,872,175
Subsequent Event [Member] | Two lawyers [Member]
Common stock, shares issued for compensation		1,000,000
Number of lawyers | Integer		2
Subsequent Event [Member] | Consultants [Member]
Common stock, shares issued for compensation	8,000,000
Number of consultants | Integer	2